Jianjun M. Gao

1 Ningde Road
Qingdao, 266073, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1).

Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1).

Journal: Drug discoveries & therapeutics

Published: August 19, 2026

Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia.

Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia.

Journal: Drug discoveries & therapeutics

Published: August 16, 2026

Clinical Characteristics and Diagnosis of Myelodysplastic Syndrome Accompanied by Eosinophilia and Basophilia.

Clinical Characteristics and Diagnosis of Myelodysplastic Syndrome Accompanied by Eosinophilia and Basophilia.

Journal: Clinical laboratory

Published: August 08, 2026

Artificial intelligence (AI)-assisted ultrasound in clinical trials: Endpoint automation, decentralized monitoring, and regulatory readiness.

Artificial intelligence (AI)-assisted ultrasound in clinical trials: Endpoint automation, decentralized monitoring, and regulatory readiness.

Journal: Drug discoveries & therapeutics

Published: April 20, 2026

The dual role of TRPA1 in dextran sulfate sodium (DSS)-induced murine colitis: Suppression alleviates acute inflammation but exacerbates subacute disease.

The dual role of TRPA1 in dextran sulfate sodium (DSS)-induced murine colitis: Suppression alleviates acute inflammation but exacerbates subacute disease.

Journal: Bioscience trends

Published: January 25, 2026

Development of Hydrophobic Tag Based HDAC6 Degrader for Ulcerative Colitis Treatment.

Development of Hydrophobic Tag Based HDAC6 Degrader for Ulcerative Colitis Treatment.

Journal: Journal of medicinal chemistry

Published: January 23, 2026

Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.

Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.

Journal: Drug discoveries & therapeutics

Published: November 19, 2025

Paltusotine: The first selective nonpeptide agonist of somatostatin receptor 2 (SSTR2) for the treatment of acromegaly.

Paltusotine: The first selective nonpeptide agonist of somatostatin receptor 2 (SSTR2) for the treatment of acromegaly.

Journal: Drug discoveries & therapeutics

Published: October 29, 2025

Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC).

Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC).

Journal: Drug discoveries & therapeutics

Published: July 13, 2025

The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease.

The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease.

Journal: Drug discoveries & therapeutics

Published: June 29, 2025

Trpa1 knockout favors colon tumorigenesis in dextran sulfate sodium (DSS)-induced colitis mice.

Trpa1 knockout favors colon tumorigenesis in dextran sulfate sodium (DSS)-induced colitis mice.

Journal: Drug discoveries & therapeutics

Published: June 22, 2025

Gepotidacin: The first-in-class triazaacenaphthylene antibiotic approved for the treatment of uncomplicated urinary tract infections.

Gepotidacin: The first-in-class triazaacenaphthylene antibiotic approved for the treatment of uncomplicated urinary tract infections.

Journal: Drug discoveries & therapeutics

Published: April 13, 2025

Showing 1-12 of 63

Last Updated: 09/26/2026